Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers

NCT02059291 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

203

Enrollment

INDUSTRY

Sponsor class

Conditions

Hereditary Periodic Fevers

Interventions

DRUG: Canakinumab
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals